Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
Submitted by
admin
on April 21, 2012 - 1:24pm
Source:
Enhanced Online News
News Tags:
Ferumoxytol
Amag Pharmaceuticals
anemia
chronic kidney disease
Headline:
AMAG Pharmaceuticals Announces a Positive CHMP Opinion for the Approval of Ferumoxytol in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
Do Not Allow Advertisers to Use My Personal information
